Ixel - dobry czy znowu przereklamowana nowosc?

IP: *.datastar.pl 10.08.02, 16:10
prosze o rzetelne info/.
    • Gość: Emilia Re: Ixel - dobry czy znowu przereklamowana nowosc IP: 2.4.STABLE* 13.08.02, 18:05
      Gość portalu: Marcin napisał(a):

      > prosze o rzetelne info/.

      tak naprawde to nie mozna przewidziec jak ty na niego zareagujesz. ja bralam
      ixel przez miesiac i mialam przez caly czas b. uciazliwe skutki uboczne:
      zawroty glowy, nagle zmiany cisnienia, ogolne oslabienie, silne bole glowy...
      Efektow pozytywnych zadnych nie bylo, wiec zmienilam lek.

    • Gość: Emilia Re: Ixel - dobry czy znowu przereklamowana nowosc2 IP: 2.4.STABLE* 13.08.02, 19:03
      Z punktu widzenia medyczno-chemicznego o ixelu (milnacipran):

      Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview
      of its antidepressant activity and clinical tolerability
      by
      Puech A, Montgomery SA,
      Prost JF, Solles A, Briley M
      Groupe Hospitalier Pitie-Salpetriere,
      Paris, France.
      Int Clin Psychopharmacol 1997 Mar; 12(2):99-108

      ABSTRACT
      Milnacipran (Ixel) is a new antidepressant with essentially equal potency for
      inhibiting the reuptake of both serotonin and noradrenaline, with no affinity
      for any neurotransmitter receptor studied. A review of the studies comparing
      milnacipran, placebo and active comparator antidepressants provides clear-cut
      evidence of its efficacy in both severe and moderate depression in hospitalized
      and community settings. Meta-analyses of the original data of controlled trials
      involving 1032 patients, comparing milnacipran with imipramine or selective
      serotonin reuptake inhibitors (SSRIs), show that milnacipran provides
      antidepressant efficacy similar to that of imipramine and significantly
      superior to that of the SSRIs. An analysis of a database of over 3300 patients
      shows that both the general and cardiovascular tolerability of milnacipran are
      superior to those of the tricyclic antidepressants (TCAs) with fewer
      cholinergic side-effects. The tolerability of milnacipran was comparable to
      that of the SSRIs, with a higher incidence of dysuria with milnacipran, and a
      higher frequency of nausea and anxiety with the SSRIs. Milnacipran is a new
      therapeutic option in depression, which offers a clinical efficacy in the range
      of the TCAs combined with a tolerability equivalent to that of the SSRIs.
Pełna wersja